By Fineline Cube 
China-based Guangzhou Innogen Pharmaceutical Group Co., Ltd. (HKG: 2591) officially launched its H-share global offering on August 7, 2025. The company plans to issue approximately 36.5564 million shares. The Hong Kong public offering constitutes 10% (around 3.6558 million shares), while the international offering accounts for 90% (around 32.9006 million shares). The offer price is set at HK$18.68 per share.
Offering Details
The subscription period commenced on August 7 and will close at noon on August 12. The shares are expected to officially begin trading on the Hong Kong Stock Exchange on August 15.
Over-Allotment Option and Trading Information
The offering includes an over-allotment option for a maximum of 5.4834 million shares. Shares will be traded in board lots of 200, with an entry fee of approximately HK$3,773.68.
IPO Sponsors and Listing
The joint sponsors for the IPO are CLSA Limited and CICC. Upon completion of the offering, the shares will commence trading on the Main Board of the Hong Kong Stock Exchange at 9:00 a.m. on August 15.-Fineline Info & Tech